Indication

Cholangiocarcinoma with IDH1 Mutation

1 clinical trial

1 product

Clinical trial

A Phase I, Multi-center, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of AB-218 for Treating Adult Patients With Advanced IDH1 Mutant Cholangiocarcinoma and Other Solid Tumors

Status: Recruiting, Estimated PCD: 2025-08-01

Product